We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Verdezyne Signs R&D Agreement for Novel Enzymes Gene Development with Syngenta

News   Feb 10, 2009

 
Verdezyne Signs R&D Agreement for Novel Enzymes Gene Development with Syngenta
 
 
 

RELATED ARTICLES

‘Shortcut’ Transforms Terpene Biosynthesis in E. Coli

News

Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.

READ MORE

Yeast Model of Metabolic Disorders May Lead to Novel Therapies

News

Researchers suggests that the role of yeast, the world's most basic eukaryotic unicellular organism, may pave the way for the development of novel, more effective therapies for the treatment of metabolic disorders.

READ MORE

Unlocking the Secret to Gene Activation

News

Researchers have made a major discovery about how “DNA binding proteins” latch onto the human genome at particular places to turn genes on or off.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE